arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

Nurix Therapeutics, Inc.

NRIX
$14.81 ▼ -1.14 (-7.15%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
32 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
18
Health
Poor
Bearish
auto_awesome

Analytical Summary

Nurix Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.7B
Dividend Yield —
Revenue Growth 8426.3% ↗
Op. Margin 83.1%
ROIC 57.8% ↗
FCF / Share $5.51 ↗
Trailing P/E 3.0x
Price / Book 1.7x
FCF Yield 37.2%
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

32-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$673.06M
↑ +8426.3% —
Net Income Profit after all expenses
$-87.17M
↓ -54.7% —
Operating Margin Operating profit as % of sales
83.1%
↑ +175.8% 0th
FCF / Share Free cash flow per share
$5.51
↑ +720.9% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑
0
Returns ↓
17
Cash Quality ↑
65

Dividend History

Dividend / share · sourced from SEC filings
$0.00 Latest / share

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 8 years · 32 quarters